Speaker: After the official discovery of the Polymerase Chain Reaction (PCR) by Dr. Kary Mullis in North America in 1983 and the development of efficient Taq Polymerase activity in 1968, years later the use of PCR in clinical practice was introduced. <\/span><\/p>\n <\/p>\n Polymerase Chain Reaction, expanded in our country due to the pandemic as it allowed the diagnosis of COVID 19 throughout the country between 2019 and 2022. <\/span><\/p>\n <\/p>\n Worldwide, the incursion of the technique in the clinic brought as a benefit, an increase in the sensitivity of detection of viral and bacterial pathogens and later it is incorporated in the specific study of human genes that tend to improve the survival of patients with genetic diseases, which, although in some cases there is no cure, allows the generation of disease management strategies that improve the quality of life. <\/span><\/p>\n <\/p>\n Today among the genomic targets frequently studied in the laboratory are: <\/strong><\/p>\n \u2713 <\/span>HLA B27: Differentiation of spondyloarthropathies. <\/span> <\/p>\n \u2713 <\/span>VF (G1691A ): This mutation increases the risk of clot formation, and thus the occurrence of both deep vein thrombosis (DVT) and\/or venous thromboembolism (VTE). <\/span> <\/p>\n \u2713 <\/span>FII (<\/span>G20210A): <\/span>This mutation increases the risk of thrombus formation. <\/span> <\/p>\n <\/p>\n For more information click on the following link: <\/span><\/p>\n
\nMaria Martinez<\/strong>
\nDegree in Biology (Mention in molecular, cellular and systems biology) from the University of Barcelona. Application Specialist (Technical Support Department) of BDR.<\/p>\n
\n